[1] HONGTHANAKORN C,CHOTIYAPUTTA W,OBERHELMAN K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t) ide analogues in clinical practice[J].Hepatology, 2011,53(6):1854-1863.
[2] CENTO V,MIRABELLI C,DIMONTE S,et al.Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution[J]. J Gen Virol, 2013,94(Pt 1):143-149.
[3] KIM J H,JUNG Y K,JOO M K,et al.Hepatitis B Viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V palymerase mutationa[J].J Korean Med Sci, 2010,25(2):257-264.
[4] WANG LP,HAN F Z,YAN X B,et al.Relationship between hepatitis B virus reverse transcriptase 181 mutation and S gene mutation in hepatitis B virus chronically infected patients[J]. Cell Mol Biol (Noisy-le-grand), 2016,62(12):18-23.
[5] WARNER N, LOCARNINI S.The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profle of viral rebound[J]. Hepatology, 2008,48(1):88-98.
[6] GAO W,HU J. Formation of hepatitis B virus covalently closed circular DNA:removal of genome-linked protein[J]. J Virol, 2007,81(12):6164-6174.
[7] LAPINSKI T W,POGORZELSKA J,FLISIAK R.HBV mutations and their clinical significance[J]. Adv Med Sci, 2012,57(1):18-22.
[8] COLLEDGE D, SOPPE S,YUEN L,et al. Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis[J]. Virology, 2017,501:70-78.
[9] LAI M W,YEH C T. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant[J]. Antivir Ther, 2008,13(7):875-879.
[10] LEE S A,KIM K,KIM H,et al. Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases[J].J Hepatol,2012,56(1):63-69.
[11] WANG M L,TANG H.Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis[J]. Hepatobiliary Pancreat Dis Int, 2016,15(6):579-586.
[12] AHN S H,PARK Y K,PARK E S,et al.The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drugresistance is potentially affected by overlapping changes in surface gene[J].J Virol,2014,88(12):6805-6818.
[13] YEH C T,CHEN Y C,HSU C W.et al.Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B[J]. BMC Cancer,2011,11(1):398.
[14] 杨松,成军.核苷(酸)类似物耐药与乙型肝炎病毒表面抗原变异[J].中华传染病杂志,2010,28(5):318-320.
[15] SLOAN R D,LJAZ S,MOORE P L,et al.Ativiral resistance mutations potentiate hepatitis B virus immune ivasion through disruption of its surface antigen a determinant[J]. Antivir Ther,2008,13(3):439-447.
[16] 俞杨,邬兰,焦杰,等.乙型肝炎病毒耐药突变对病毒表面抗原编码区的影响[J].国际检验医学杂志,2013,34(12):1518-1520.
[17] MENENDEZ-ARIAS L,AVAREZ M,PACHECO B.Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase:mechanism of action and resistance[J].Curr Opin Virol,2014,8(5):1-9.
[18] ZHOU L Y,CHEN E Q,WANG M L,et al.Biological characteristics comparison of HBV rtA181T mutants with truncated or substituted HBsAg expression in vitro and in vivo model systems[J]. Sci Rep, 2016,6:39260. |
